Tenderwize
Retour à la recherche

Open-house rebate agreement for Eltrombopag

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 7 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eltrombopag, ATC B02BX05

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

48 / 100

Facteurs de risque

Submission is only valid if the chosen format requirements are met: handwritten paper originals in duplicate or electro...

Participation is restricted to pharmaceutical companies, and suitability must be demonstrated by a signed declaration o...

Submission deadline in 7 days

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Non-exclusive rebate agreements for the active substance Eltrombopag (ATC B02BX05).
  • Supply contract for pharmaceutical products.
Afficher le résumé complet

This is an open-house pharmaceutical supply arrangement for Eltrombopag (ATC B02BX05) offered by AOK Bayern to all interested pharmaceutical companies that meet the stated eligibility requirement. It is not a competitive award procedure in the usual sense: no selection among bidders, identical non-negotiable contract terms, and no explicit award criteria. Contracting is possible throughout the term, with the latest contract conclusion date stated as 2026-09-05. Submission is possible electronically with a qualified electronic signature via DTVP or in paper form in duplicate originals.

Risques

Submission is only valid if the chosen format requirements are met: handwritten paper originals in duplicate or electro...

Participation is restricted to pharmaceutical companies, and suitability must be demonstrated by a signed declaration o...

Submission deadline in 7 days

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Eltrombopag

Single lot for non-exclusive open-house rebate agreements for the medicinal product Eltrombopag, ATC B02BX05. Scope is pharmaceutical supplies in Germany (place of performance: DEU, DE212). The lot is described as an open-house model with identical, non-individually negotiated contract terms.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Oct 2024 - Oct 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Sep 05, 2026

Détails de la procédure

Date de publication
16 Sep 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
558406-2024

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30